Global Phase 3 Study Of IMC-1121B In Metastatic Breast Cancer Commences

[News]

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.

More... (http://www.medicalnewstoday.com/articles/118498.php)